Casadei, B., Pellegrini, C., Pulsoni, A., Annechini, G., De Renzo, A., Stefoni, V., . . . Zinzani, P. L. (2016). 90‐yttrium‐ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high‐risk follicular lymphoma: Updated long‐term results after a median follow‐up of 7 years. Cancer Med.
Citação norma ChicagoCasadei, Beatrice, et al. "90‐yttrium‐ibritumomab Tiuxetan Consolidation of Fludarabine, Mitoxantrone, Rituximab in Intermediate/high‐risk Follicular Lymphoma: Updated Long‐term Results After a Median Follow‐up of 7 years." Cancer Med 2016.
MLA CitationCasadei, Beatrice, et al. "90‐yttrium‐ibritumomab Tiuxetan Consolidation of Fludarabine, Mitoxantrone, Rituximab in Intermediate/high‐risk Follicular Lymphoma: Updated Long‐term Results After a Median Follow‐up of 7 years." Cancer Med 2016.